The impact of amyloid‐beta and tau on prospective cognitive decline in older individuals
Reisa A. Sperling(Harvard University), Keith A. Johnson(Brigham and Women's Hospital), Rebecca A. Betensky(Harvard University), Dylan Kirn(Brigham and Women's Hospital), Rachel F. Buckley(Harvard University), Jennifer S. Rabin(Sunnybrook Health Science Centre), Jonathan Jackson(Harvard University), Bernard Hanseeuw(Cliniques Universitaires Saint-Luc), Jennifer R. Gatchel(Harvard University), Yakeel T. Quiroz(Harvard University), Heidi I.L. Jacobs(Harvard University), Nancy J. Donovan(Brigham and Women's Hospital), Hyun‐Sik Yang(Broad Institute), Trey Hedden(Harvard University), Kathryn V. Papp(Brigham and Women's Hospital), Dorene M. Rentz(Brigham and Women's Hospital), Elizabeth C. Mormino(Allen Institute for Brain Science), Rebecca E. Amariglio(Harvard University), Michael J Properzi(Massachusetts General Hospital), Jasmeer P. Chhatwal(Harvard University), Gad A. Marshall, Aaron P. Schultz(Harvard University)
Cited by 289
Related Papers
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
|Alzheimer s & Dementia|2018|10.4k
Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
|Alzheimer s & Dementia|2011|7.1k
Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease
|New England Journal of Medicine|2012|3.8k
A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease
|Alzheimer s & Dementia|2014|3.1k